316 related articles for article (PubMed ID: 19835938)
1. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
Shukla A; Katare OP; Singh B; Vyas SP
Int J Pharm; 2010 Jan; 385(1-2):47-52. PubMed ID: 19835938
[TBL] [Abstract][Full Text] [Related]
2. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization.
Singh P; Prabakaran D; Jain S; Mishra V; Jaganathan KS; Vyas SP
Int J Pharm; 2004 Jul; 278(2):379-90. PubMed ID: 15196642
[TBL] [Abstract][Full Text] [Related]
3. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes).
Shukla A; Khatri K; Gupta PN; Goyal AK; Mehta A; Vyas SP
J Pharm Pharm Sci; 2008; 11(1):59-66. PubMed ID: 18445364
[TBL] [Abstract][Full Text] [Related]
4. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization.
Gupta PN; Vyas SP
Colloids Surf B Biointerfaces; 2011 Jan; 82(1):118-25. PubMed ID: 20843665
[TBL] [Abstract][Full Text] [Related]
5. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
6. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
7. Cationic transfersomes based topical genetic vaccine against hepatitis B.
Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
[TBL] [Abstract][Full Text] [Related]
8. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B.
Jain S; Singh P; Mishra V; Vyas SP
Immunol Lett; 2005 Oct; 101(1):41-9. PubMed ID: 15869802
[TBL] [Abstract][Full Text] [Related]
9. Elastic liposomes mediated transcutaneous immunization against Hepatitis B.
Mishra D; Dubey V; Asthana A; Saraf DK; Jain NK
Vaccine; 2006 May; 24(22):4847-55. PubMed ID: 16600441
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.
Feng L; Qi XR; Zhou XJ; Maitani Y; Wang SC; Jiang Y; Nagai T
J Control Release; 2006 May; 112(1):35-42. PubMed ID: 16516999
[TBL] [Abstract][Full Text] [Related]
11. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes.
Mishra D; Mishra PK; Dubey V; Nahar M; Dabadghao S; Jain NK
Eur J Pharm Sci; 2008 Apr; 33(4-5):424-33. PubMed ID: 18359615
[TBL] [Abstract][Full Text] [Related]
12. Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen.
Tiwari S; Verma SK; Agrawal GP; Vyas SP
Int J Pharm; 2011 Jul; 413(1-2):211-9. PubMed ID: 21540094
[TBL] [Abstract][Full Text] [Related]
13. PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B.
Jain AK; Goyal AK; Mishra N; Vaidya B; Mangal S; Vyas SP
Int J Pharm; 2010 Mar; 387(1-2):253-62. PubMed ID: 20005936
[TBL] [Abstract][Full Text] [Related]
14. Nanodecoy system: a novel approach to design hepatitis B vaccine for immunopotentiation.
Goyal AK; Rawat A; Mahor S; Gupta PN; Khatri K; Vyas SP
Int J Pharm; 2006 Feb; 309(1-2):227-33. PubMed ID: 16406404
[TBL] [Abstract][Full Text] [Related]
15. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response.
Chen KS; Strober W
Eur J Immunol; 1990 Feb; 20(2):433-6. PubMed ID: 2311649
[TBL] [Abstract][Full Text] [Related]
16. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP
J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638
[TBL] [Abstract][Full Text] [Related]
17. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
Prego C; Paolicelli P; Díaz B; Vicente S; Sánchez A; González-Fernández A; Alonso MJ
Vaccine; 2010 Mar; 28(14):2607-14. PubMed ID: 20096389
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of group-specific a antigen in hepatitis B vaccines by anti-HBs/a monoclonal antibody.
Yamamoto H; Satoh T; Kiyohara T; Totsuka A; Moritsugu Y
Biologicals; 1997 Dec; 25(4):373-80. PubMed ID: 9467033
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.
Pandey RS; Dixit VK
J Drug Target; 2010 May; 18(4):282-91. PubMed ID: 19958131
[TBL] [Abstract][Full Text] [Related]
20. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
McCluskie MJ; Davis HL
J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
